Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2014 - 2026)
Zevra Therapeutics' (ZVRA) quarterly Total Non-Current Liabilities came in at $70.9 million in Q1 2026, down 38.61% YoY from $115.5 million in Q1 2025, and down 42.37% on a QoQ basis from $123.0 million in Q4 2025.
Zevra Therapeutics (ZVRA) Total Non-Current Liabilities (2014 - 2026) Analysis & Trends
Zevra Therapeutics (ZVRA) has 13 years of Total Non-Current Liabilities data on file, last reported at $70.9 million in Q1 2026.
- Quarterly Total Non-Current Liabilities fell 38.61% year-over-year to $70.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $70.9 million (down 38.61% YoY) and the FY2025 annual result came in at $123.0 million, up 1.98% from the prior year.
- Total Non-Current Liabilities eased to $70.9 million in Q1 2026, from $123.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $135.7 million in Q2 2025 to a low of -$8.5 million in Q1 2022.
- A 5-year average of $81.8 million and a median of $94.1 million in 2023 frame the typical range for Total Non-Current Liabilities.
- The widest YoY moves for Total Non-Current Liabilities: up 593.97% in 2022, down 237.36% in 2022.
- Tracing ZVRA's Total Non-Current Liabilities over 5 years: stood at $40.2 million in 2022, then surged by 134.76% to $94.4 million in 2023, then rose by 27.86% to $120.7 million in 2024, then rose by 1.98% to $123.0 million in 2025, then tumbled by 42.37% to $70.9 million in 2026.
- The last three Total Non-Current Liabilities figures came in at $70.9 million (Q1 2026), $123.0 million (Q4 2025), and $133.0 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 40.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.53 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.88 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.32 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.17 Bn |
| 10 | Zevra Therapeutics | 671.75 Mn | 450.18 Mn | 38.18 Mn | 71.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 71.90 Mn |
| Mar 31, 2026 | 70.92 Mn |
| Dec 31, 2025 | 123.05 Mn |
| Sep 30, 2025 | 132.96 Mn |
| Jun 30, 2025 | 135.73 Mn |
| Mar 31, 2025 | 115.52 Mn |
| Dec 31, 2024 | 120.66 Mn |
| Sep 30, 2024 | 116.26 Mn |
| Jun 30, 2024 | 105.29 Mn |
| Mar 31, 2024 | 93.93 Mn |
| Dec 31, 2023 | 94.36 Mn |
| Sep 30, 2023 | 71.51 Mn |
| Mar 31, 2023 | 35.58 Mn |
| Dec 31, 2022 | 40.20 Mn |
| Sep 30, 2022 | 25.73 Mn |
| Jun 30, 2022 | 35.58 Mn |
| Mar 31, 2022 | -8.48 Mn |
| Dec 31, 2021 | 5.79 Mn |
| Sep 30, 2021 | 5.05 Mn |
| Jun 30, 2021 | 8.10 Mn |